Antisense Oligonucleotides for Neurodegeneration

Antisense Oligonucleotides for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotides for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">RNase H-Mediated Degradation</td>
<td>ASO-RNA hybrid recruits RNase H to cleave RNA</td>
</tr>
<tr>
<td class="label">Steric Blockade</td>
<td>Blocks translation initiation or splicing machinery</td>
</tr>
<tr>
<td class="label">RNA Silencing</td>
<td>Uses RNA interference pathways</td>
</tr>
<tr>
<td class="label">Splice Modulation</td>
<td>Corrects aberrant splicing patterns</td>
</tr>
<tr>
<td class="label">Allele-Specific Targeting</td>
<td>Targets mutant allele while sparing wild-type</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[Tau](/proteins/tau) (MAPT)</td>
</tr>
<tr>
<td class="label">ASO-GC</td>
<td>GC (MIR137)</td>
</tr>
<tr>
<td class="label">ASO-α-syn</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">[C9orf72](/entities/c9orf72)</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ATXN2-ASO</td>
<td>ATXN2</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT03761849</td>
<td>Tominersen</td>
</tr>
<tr>
<td class="label">NCT02644599</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">NCT03

...

Antisense Oligonucleotides for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotides for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">RNase H-Mediated Degradation</td>
<td>ASO-RNA hybrid recruits RNase H to cleave RNA</td>
</tr>
<tr>
<td class="label">Steric Blockade</td>
<td>Blocks translation initiation or splicing machinery</td>
</tr>
<tr>
<td class="label">RNA Silencing</td>
<td>Uses RNA interference pathways</td>
</tr>
<tr>
<td class="label">Splice Modulation</td>
<td>Corrects aberrant splicing patterns</td>
</tr>
<tr>
<td class="label">Allele-Specific Targeting</td>
<td>Targets mutant allele while sparing wild-type</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[Tau](/proteins/tau) (MAPT)</td>
</tr>
<tr>
<td class="label">ASO-GC</td>
<td>GC (MIR137)</td>
</tr>
<tr>
<td class="label">ASO-α-syn</td>
<td>SNCA</td>
</tr>
<tr>
<td class="label">[C9orf72](/entities/c9orf72)</td>
<td>C9orf72</td>
</tr>
<tr>
<td class="label">ATXN2-ASO</td>
<td>ATXN2</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT03761849</td>
<td>Tominersen</td>
</tr>
<tr>
<td class="label">NCT02644599</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">NCT03186118</td>
<td>Nusinersen</td>
</tr>
<tr>
<td class="label">NCT04784160</td>
<td>BIIB080</td>
</tr>
<tr>
<td class="label">NCT04297605</td>
<td>IONIS-C9Rx</td>
</tr>
</table>

Introduction

Antisense Oligonucleotides For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA or RNA molecules designed to bind to specific messenger RNA (mRNA) sequences, thereby modulating gene expression. ASOs represent a transformative therapeutic modality for neurodegenerative diseases, enabling targeted reduction of toxic protein aggregates, correction of aberrant splicing, and allele-specific silencing of disease-causing mutations. Several ASOs have now received FDA approval for neurological disorders, with numerous candidates in clinical development for Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). [@fda2023]

Molecular Mechanism

ASOs employ several mechanisms to achieve therapeutic effects: [@tabrizi2019]

Key Drug Candidates

Tominersen (RG6042)

• Target: [HTT](/genes/htt) mRNA (mutant huntingtin)
• Mechanism: Allele-nonspecific ASO reduces both mutant and wild-type HTT
• Clinical Status: Phase III (GENERATION-HD1) - development discontinued
• Evidence: Reduced CSF mutant [huntingtin](/proteins/huntingtin-protein) in Phase I/II trials

Inotersen (Tegsedi)

• Target: TTR (transthyretin) mRNA
• Mechanism: Reduces both mutant and wild-type TTR production
• FDA Status: FDA-approved for hATTR polyneuropathy
• Evidence: 79% reduction in TTR protein; improved neuropathy

Nusinersen (Spinraza)

• Target: SMN2 mRNA (splicing correction)
• Mechanism: Promotes inclusion of exon 7, increasing SMN protein
• FDA Status: FDA-approved for spinal muscular atrophy
• Evidence: Significant improvement in motor function

Tofersen (Qalsody)

• Target: SOD1 mRNA
• Mechanism: Reduces mutant SOD1 protein production
• FDA Status: FDA-approved for SOD1-ALS (2023)
• Evidence: Reduced CSF SOD1, slowed clinical decline

ASOs in Development

Disease-Specific Applications

Huntington's Disease

• Tominersen (RG6042): Reduced mHTT by ~40% in CSF
• GENERATION-HD1 trial enrolled ~800 patients
• Development discontinued but ASO approach validated
• Next-generation ASOs with improved delivery in development

Amyotrophic Lateral Sclerosis

• Tofersen (Qalsody): First FDA-approved ASO for ALS (SOD1)
• Targeting C9orf72, ATXN2, FUS in development
• Combination with small molecules in trials

Alzheimer's Disease

• BIIB080 (IONIS-MAPTRx): Anti-[tau](/proteins/tau) ASO
• Phase I/II showed dose-dependent reduction in CSF tau
• Prevents spread of tau pathology
• [Aβ](/proteins/amyloid-beta)-targeting ASOs in preclinical development

Parkinson's Disease

• ASOs targeting SNCA (α-synuclein) in development
• GBA1 gene modulation to enhance glucocerebrosidase
• LRRK2-targeting ASOs in preclinical stages

Spinal Muscular Atrophy

• Nusinersen (Spinraza): Landmark FDA approval 2016
• Risdiplam (Evrysdi): Small molecule splice modifier
• Onasemnogene abeparvovec (Zolgensma): Gene therapy

Clinical Trials

Delivery Challenges and Solutions

Blood-Brain Barrier Penetration

• ASOs require intrathecal (lumbar puncture) delivery
• Conjugation to receptor ligands (e.g., transferrin receptor)
• Novel formulations (lipid nanoparticles, exosomes)

Safety Considerations

• Off-target effects monitoring required
• Spinal muscular atrophy patients require careful monitoring
• Dose-dependent liver enzyme elevation possible

Research Directions

Current research focuses on:

• Brain-penetrant ASOs for intravenous administration
• Allele-specific ASOs for dominant-negative mutations
• Combination approaches with gene therapy
• Biomarker development for patient selection
• Repeat-dosing protocols for sustained benefit

See Also

• [Tominersen](/therapeutics/tominersen-huntingtons)
• [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)
• [SOD1 Gene](/proteins/sod1-protein)
• [HTT Gene](/htt-gene)
• [C9orf72 Gene](/proteins/c9orf72-protein)

External Links

• [FDA Approval Summary - Tofersen](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-approves-qalsody-tofersen-sod1-als)
• [ClinicalTrials.gov - ASO Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=antisense+oligonucleotide)
• [Ionis Pharmaceuticals Pipeline](https://www.ionispharma.com/pipeline/)

External Links

• [PubMed - PGC-1 Alpha Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PGC-1alpha+neurodegeneration)
• [NIH - Mitochondrial Biogenesis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/)
• [Nature - PGC-1 Alpha and Parkinson's](https://www.nature.com/articles/ncomms3033)
• [Cell - Mitochondrial Dynamics](https://www.sciencedirect.com/science/article/pii/S1550413115000537)
• [Alzheimer's Research - Mitochondria](https://www.alzheimersresearchuk.org/dementia-topics/mitochondria/)

Background

The study of Antisense Oligonucleotides For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Bennett CF, et al, Antisense oligonucleotide therapeutics for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36653987/)

Unknown, FDA. Qalsody (tofersen) injection approval letter. 2023 (2023)

[Tabrizi SJ, et al, Targeting huntingtin protein in Huntington's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31397647/)

[Miller T, et al, Phase 1-2 trial of tofersen for SOD1 ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32640130/)

[Mercuri E, et al, Nusinersen in spinal muscular atrophy (2018)](https://pubmed.ncbi.nlm.nih.gov/29747944/)

[Mummery CJ, et al, BIIB080 (IONIS-MAPTRx) in mild Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36534356/)

[Hu J, et al, Allele-specific silencing of mutant huntingtin (2020)](https://pubmed.ncbi.nlm.nih.gov/32632293/)

[Kordas G, et al, Antisense oligonucleotides for Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35716074/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;